Table 2 Results of antimicrobial susceptibility of BH15-2 and BH16-24.

β-lactams

Aminoglycosides

Penicillin(10U)

≤ 19

20–27

≥ 28

44 (S)

10 (R)

Neomycin(30)

≤ 16

17–23

≥ 24

22 (I)

19 (I)

Ampicilin(10)

≤ 13

14–16

≥ 17

28 (S)

14 (I)

Gentamycin(10)

≤ 15

16–23

≥ 24

17 (I)

18 (I)

Ceftazidime(30)

≤ 17

18–20

≥ 21

30 (S)

8 (R)

Spectinomycin(100)

≤ 14

15–18

≥ 19

19 (S)

11 (R)

Cefazolin(30)

≤ 10

10–20

≥ 20

46 (S)

14 (I)

Macrolides

Ceftriaxone Sodium(30)

≤ 13

14–22

≥ 23

42 (S)

15 (I)

Erythromycin(15)

≤ 13

14–22

≥ 23

32 (S)

27 (S)

Sulfonamides

Azithromycin(15)

≤ 13

14–17

≥ 18

20 (S)

19 (S)

Sulfasomizole(300)

≤ 12

13–16

≥ 17

34 (S)

0 (R)

Quinolones

Compound Sulfamethoxazole(1.25/23.75)

≤ 10

11–15

≥ 16

24 (S)

0 (R)

Ciprofloxacin(5)

≤ 15

16–20

≥ 21

38 (S)

25 (S)

Tetracyclines

Norfloxacin(10)

≤ 12

13–16

≥ 17

21 (S)

22 (S)

Tetracycline(30)

≤ 14

15–18

≥ 19

32 (S)

22 (S)

Chloramphenicol

Deoxytetracycline(30)

≤ 17

18–22

≥ 23

36 (S)

24 (S)

Chloramphenicol(30)

≤ 12

13–17

≥ 18

34 (S)

24 (S)

Rifamycin

Polypeptide

Rifampin(5)

≤ 16

17–19

≥ 20

35 (S)

14 (R)

Polymyxin B(300U)

≤ 8

9–11

≥ 12

13 (S)

0 (R)